Share on LinkedInShare on LinkedIn

ARTICLE · 01 APRIL 2026

Paraquat (Gramoxone®) Parkinson's Class Action Certification Upheld On Appeal In British Columbia

Since 2021, Siskinds LLP has represented the plaintiffs in proposed paraquat (Gramoxone®) class actions across Canada, alleging that paraquat exposure is associated with an increased risk of developing Parkinson's disease.

GlobalLitigation, Mediation & Arbitration

Since 2021, Siskinds LLPhas represented the plaintiffs in proposed paraquat (Gramoxone®) class actions across Canada, alleging that paraquat exposure is associated with an increased risk of developing Parkinson's disease. These Canadian paraquat lawsuits allege that paraquat carries a serious health hazard, namely, the risk of Parkinson's disease for individuals who used and/or were exposed to the herbicide.

The claims further allege that the manufacturers of paraquat, including Syngenta AG and its subsidiaries, failed to adequately warn consumers, agricultural workers, and applicators about the risk of Parkinson's disease, failed to provide proper safety instructions on how to protect against exposure, and knew or ought to have known of the scientific evidence linking paraquat to Parkinson's disease. It is also alleged that the manufacturers failed to conduct adequate long-term safety studies before and after marketing Gramoxone® paraquat products in Canada.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from